<DOC>
	<DOCNO>NCT02646111</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety triple therapy AbbVie adult chronic hepatitis C virus ( `` HCV '' ) , respond prior treatment protease inhibitor . The `` Triple therapy '' AbbVie attack various site viral genome , thus increase potential efficacy treatment , especially patient fail PI treatment .</brief_summary>
	<brief_title>Ombitasvir/Paritaprevir/Ritonavir Dasabuvir With Without Ribavirin Protease-Inhibitors ( `` PI '' ) Failures</brief_title>
	<detailed_description>Patients genotype 1 HCV , underwent past triple therapy ( Telaprevir , Boceprevir Simeprevir Pegylated interferon / Ribavirin ) non-responders , partial responder relapse - screen research center 30 day first treatment . At end initial assessment - recruited participant allocate different treatment group accordance hepatitis virus subtype 1a , 1b presence cirrhosis , follow : - Group A - genotype 1b without cirrhosis - 12 week treatment * - Group B - genotype 1b cirrhosis - 12 week treatment - Group C - genotype 1a without cirrhosis - 12 week treatment - Group D - genotype 1a cirrhosis - 24 week treatment ( * Only group get Ribavirin ) During treatment period , participant ask describe treatment 's tolerability ( term side effect ) use self-administered questionnaire : SF-36 , WPAI Hep C v2.0 . The follow also include physical assessment , side effect documentation , blood test , abdominal Ultrasound Fibroscan .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Diagnosis hepatitis C , genotype 1A 1B . Documentation PI failure treatment least 12 month prior study entry . Patients cirrhosis ( patient cirrhosis Child A 5 point ) . Inability stay study 36 week . Diagnosis crosscontamination HIV Hepatitis B virus . Renal disfunction ( creatinine clearance &lt; 30 ml / min ) . Evidence hepatic carcinoma . Another serious disease , may interfere study . Pregnant / breastfeed woman . Men pregnant partner . Drug alcohol abuse six month precede study . Chronic liver disease hepatitis C ( Primary biliary cirrhosis , Primary sclerosing cholangitis , Autoimmune hepatitis ) . Current treatment HCV . Past PI Failure due adverse event . Patients cirrhosis Child B . Patients cirrhosis , child B improve child A treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>`` Hepatitis C Virus ''</keyword>
	<keyword>`` Triple Therapy ''</keyword>
	<keyword>`` PI Failure ''</keyword>
	<keyword>`` Genotype 1 ''</keyword>
</DOC>